Navigation Links
Advanced-stage ovarian cancer patients with BRCA live longer, may respond better to treatment
Date:3/10/2008

Tampa, Fla. - Two abstracts underscoring the importance of testing for BRCA1/2 mutations in women with ovarian cancer were presented at this week's Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancers, by researchers from The University of Texas M. D. Anderson Cancer Center.

In the first study, a multicenter research team led by M.D. Anderson found advanced- stage ovarian cancer patients with non-Ashkenazi Jewish BRCA (non-AJ BRCA) mutations experience longer progression-free and overall survival rates compared to those with sporadic ovarian cancer. The data confirms previous research which reported that among ovarian cancer patients of Ashkenazi-Jewish heritage, BRCA1/2 mutations (AJ BRCA) are associated improved long-term survival.

For this study, researchers examined 85 advanced-stage ovarian cancer patients with non-AJ BRCA mutations and 116 patients who did not express any type of BRCA mutation. Compared to patients without BRCA mutations, non-AJ BRCA carriers had longer progression-free survival of 19.0 vs. 27.8 months and improved overall survival of 65.6 vs. 101.4 months. Non-AJ BRCA patients had a 2.15 times greater odds of complete response to initial chemotherapy response over sporadic, non-carrier patients.

Karen Lu, M.D., associate professor in the Department of Gynecologic Oncology at M. D. Anderson and senior author on the study said the difference in survival rates indicate that individuals with BRCA mutations might respond better to standard chemotherapy for ovarian cancer. "Thus, it becomes increasingly valuable to know a patient's BRCA status to guide and personalize treatment decisions," Lu said.

Majority of Patients Unaware BRCA Testing Available

A second study conducted at M. D. Anderson concluded that, despite being available for more than 10 years, a majority of women with ovarian cancer were unaware genetic counseling and testing for BRCA1/2 mutations was an option. Of the 225 ovarian cancer patients surveyed, 56 percent had not heard of BRCA testing. This lack of awareness was more profound in minorities - 69 percent of Hispanic and 88 percent of African American respondents were unaware of BRCA testing compared to 52 percent of white women.

"Patients typically associate genetic testing with benefiting family members and offspring," Lu said. "Both of these studies illustrate that it is equally important for the cancer patient to get information from their doctors about genetic testing because it not only has implications for their family, but their own treatment and prognosis."

She said that more than 85 percent of ovarian cancer patients surveyed would be willing to undergo BRCA testing if it would affect their care, but the cost of testing may be a barrier. "Currently, oncologists are inconsistent in their testing for BRCA mutations. Based on the treatment implications of our findings and the surprisingly low knowledge that such testing is available, we recommend developing ways to systematically evaluate every ovarian cancer patient for BRCA," Lu said.

A family history of breast and/or ovarian cancer is reported in approximately five percent to 15 percent of ovarian cancer cases, with BRCA1/2 mutations expressed in a significant proportion of these cases.


'/>"/>

Contact: Robyn Stein
robyn.stein@gabbe.com
212-220-4444
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinsons Disease
2. Gleevec May Disrupt Ovarian Function
3. U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer
4. Researchers identify and shut down protein that fuels ovarian cancer
5. Combo Treatment Best for Melanoma, Advanced Ovarian Cancer
6. Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
7. Yale test detects early stage ovarian cancer with 99 percent accuracy
8. Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
9. Oral Contraceptives Cut Ovarian Cancer Risk
10. Caffeine May Lower Ovarian Cancer Risk
11. Ovarian cancer risk not affected by alcohol and smoking, but reduced by caffeine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Houston ... at his office, Antoine Dental Center. Currently, patients can get single dental implants ... apply, but patients can learn more about these offers by contacting Antoine Dental ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age ... Oxford University predict that 47 percent of all jobs in the United States may ... and “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management ... radiology marketing programs at the annual Building Better Radiology Marketing Programs conference, ... Hotel in Fort Worth, Texas. Nine awards are given out in five categories. They ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, 2017 the ... to withdraw previous guidance issued by the Obama Administration requiring schools to ... May 2016 by the Obama Administration came in response to a growing number ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs ... benchmarks in the global Oesophageal Cancer market. The research ... the key drugs marketed for Oesophageal Cancer and their clinical attributes? ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... York , February 23, 2017 ... arising from increasing caseload for varicose veins in their ... the globe are prompting the adoption of endovenous laser ... on global endovenous laser therapy market, published ... aftereffects of lifestyle choices and consequences of obesity have ...
Breaking Medicine Technology: